Nature Reviews Clinical Oncology

Article	Citations
Clinical development and potential of photothermal and photodynamic therapies for cancer	1567
Broadening horizons: the role of ferroptosis in cancer	1155
Targeting apoptosis in cancer therapy	1123
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood	779
Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors	657
PD-L1 as a biomarker of response to immune-checkpoint inhibitors	616
Immunotherapies for hepatocellular carcinoma	609
Liquid biopsy enters the clinic — implementation issues and future challenges	580
Exploring the NK cell platform for cancer immunotherapy	569
The tumour microenvironment in pancreatic cancer — clinical challenges and opportunities	559
Unlocking the potential of antibody–drug conjugates for cancer therapy	484
Advances in the development of personalized neoantigen-based therapeutic cancer vaccines	462
Clinical and therapeutic relevance of cancer-associated fibroblasts	397
TGFβ biology in cancer progression and immunotherapy	395
Treatment landscape of triple-negative breast cancer — expanded options, evolving needs	389
Roles and mechanisms of alternative splicing in cancer — implications for care	374
The emerging roles of circRNAs in cancer and oncology	368
Immune-checkpoint inhibitors: long-term implications of toxicity	341
Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways	340
Advancing therapy for osteosarcoma	309
Planning for tomorrow: global cancer incidence and the role of prevention 2020–2070	302
Harnessing cytokines and chemokines for cancer therapy	297
T cell-engaging therapies — BiTEs and beyond	282
Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic	280
The SWI/SNF complex in cancer — biology, biomarkers and therapy	279

Rising incidence of early-onset colorectal cancer — a call to action	259
The adenosine pathway in immuno-oncology	258
Exploiting the folate receptor α in oncology	251
Lineage plasticity in cancer: a shared pathway of therapeutic resistance	247
Clinical relevance of tumour-associated macrophages	242
The MYC oncogene — the grand orchestrator of cancer growth and immune evasion	239
HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management	229
Predicting cancer outcomes with radiomics and artificial intelligence in radiology	210
Lung cancer LDCT screening and mortality reduction — evidence, pitfalls and future perspectives	210
ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper	206
Nasopharyngeal carcinoma: an evolving paradigm	195
Intratumoural administration and tumour tissue targeting of cancer immunotherapies	194
Understanding and overcoming resistance to PARP inhibitors in cancer therapy	193
Moving towards personalized treatments of immune-related adverse events	184
Therapeutic targeting of the hypoxic tumour microenvironment	176
Clinical implications of T cell exhaustion for cancer immunotherapy	170
Beyond conventional immune-checkpoint inhibition — novel immunotherapies for renal cell carcinoma	169
Personalized early detection and prevention of breast cancer: ENVISION consensus statement	166
B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome	165
Targeting drugs to tumours using cell membrane-coated nanoparticles	164
Targeting cancer-promoting inflammation — have anti-inflammatory therapies come of age?	160
Tumour budding in solid cancers	159
Artificial intelligence in radiation oncology	156
MET-dependent solid tumours — molecular diagnosis and targeted therapy	156
Anti-angiogenic agents — overcoming tumour endothelial cell anergy and improving immunotherapy outcomes	154
The implications of IDH mutations for cancer development and therapy	150
CAR T cell therapies for patients with multiple myeloma	150
Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics	149
Evolution of systemic therapy for stages I–III non-metastatic non-small-cell lung cancer	143
Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC	143
Senescence and cancer — role and therapeutic opportunities	136
A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains	133
Applying high-dimensional single-cell technologies to the analysis of cancer immunotherapy	133
Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm	132
Towards precision medicine for AML	130
Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management	129
COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety	127
Immunogenicity of CAR T cells in cancer therapy	123
ROS1-dependent cancers — biology, diagnostics and therapeutics	122
Towards new horizons: characterization, classification and implications of the tumour antigenic repertoire	118
The current state of the art and future trends in RAS-targeted cancer therapies	118
Fundamentals and developments in fluorescence-guided cancer surgery	117
The emerging role of photoacoustic imaging in clinical oncology	115
Is early-onset cancer an emerging global epidemic? Current evidence and future implications	114
Long-term outcomes following CAR T cell therapy: what we know so far	110
Precision oncology in metastatic colorectal cancer — from biology to medicine	108
The nuclear export protein XPO1 — from biology to targeted therapy	108
Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion	107
Integrating evolutionary dynamics into cancer therapy	107
The blood–tumour barrier in cancer biology and therapy	104

Tumour burden and efficacy of immune-checkpoint inhibitors	102
Advancing therapy for neuroblastoma	95
EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment	94
COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials	94
Protein degraders enter the clinic — a new approach to cancer therapy	93
Circulating tumour DNA — looking beyond the blood	92
Strategies for the successful implementation of plasma-based NSCLC genotyping in clinical practice	91
International consensus recommendations on key outcome measures for organ preservation after (chemo)radiotherapy in patients with rectal cancer	89
Radiotheranostics in oncology: current challenges and emerging opportunities	89
Novel approaches to target the microenvironment of bone metastasis	88
Therapy with oncolytic viruses: progress and challenges	76
Dissecting the biology of allogeneic HSCT to enhance the GvT effect whilst minimizing GvHD	76
Provision of cancer care during the COVID-19 pandemic	73
Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer	73
Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention	71
The emerging roles of γδ T cells in cancer immunotherapy	69
Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours	69
Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide	67
COVID-19 and cancer: what we know so far	67
Towards clinical translation of FLASH radiotherapy	66
Beneficial autoimmunity improves cancer prognosis	61
Progress in refining the clinical management of cancer of unknown primary in the molecular era	60
Histology-agnostic drug development — considering issues beyond the tissue	58
Consequences of COVID-19 for cancer care — a CRUK perspective	58
Neoadjuvant therapy for pancreatic cancer	56
Single-cell profiling of tumour evolution in multiple myeloma — opportunities for precision medicine	56
Cancer and COVID-19 — potentially deleterious effects of delaying radiotherapy	55
Thermal immuno-nanomedicine in cancer	54
At a crossroads: how to translate the roles of PI3K in oncogenic and metabolic signalling into improvements in cancer therapy	53
Immunotherapy discontinuation — how, and when? Data from melanoma as a paradigm	53
Humanized mouse models for immuno-oncology research	52
The multiple roles of LDH in cancer	50
Older adults with cancer and their caregivers — current landscape and future directions for clinical care	50
The global burden of lung cancer: current status and future trends	50
The immune landscape of common CNS malignancies: implications for immunotherapy	48
Integrated MRI-guided radiotherapy — opportunities and challenges	44
Informative censoring — a neglected cause of bias in oncology trials	41
New treatment strategies for advanced-stage gastrointestinal stromal tumours	40
Gut microbiota in colorectal cancer development and therapy	40
Harnessing big data to characterize immune-related adverse events	39
The oligometastatic spectrum in the era of improved detection and modern systemic therapy	38
Criteria for the translation of radiomics into clinically useful tests	37
Advances in the clinical management of uveal melanoma	37
Beyond the storm — subacute toxicities and late effects in children receiving CAR T cells	36
Cancer-associated cachexia — understanding the tumour macroenvironment and microenvironment to improve management	34
Predicting tumour radiosensitivity to deliver precision radiotherapy	34
The roles and implications of RNA m6A modification in cancer	32
Liquid biopsy for early stage lung cancer moves ever closer	32
Global trends in the epidemiology of bladder cancer: challenges for public health and clinical practice	32
Treatment-free remission in patients with chronic myeloid leukaemia	31
Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer	31
Systemic therapy for early-stage breast cancer: learning from the past to build the future	31
Towards precision oncology with patient-derived xenografts	31
Emerging evidence for adapting radiotherapy to immunotherapy	30
Advancing CAR T cell therapy through the use of multidimensional omics data	29
COVID-19 and cancer: do we really know what we think we know?	29
The clinical development of antibody–drug conjugates — lessons from leukaemia	28
At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC	28
The changing landscape of cancer in the USA — opportunities for advancing prevention and treatment	28
Circulating tumour cells for early detection of clinically relevant cancer	25
Mitigating acute chemotherapy-associated adverse events in patients with cancer	25
COVID-19 in patients with cancer: managing a pandemic within a pandemic	25
Cancer-related accelerated ageing and biobehavioural modifiers: a framework for research and clinical care	24
The role of genomics in global cancer prevention	22
Nano-omics: nanotechnology-based multidimensional harvesting of the blood-circulating cancerome	22
Cholangiocarcinoma — novel biological insights and therapeutic strategies	21
Methylation extends the reach of liquid biopsy in cancer detection	20
Will allogeneic CAR T cells for CD19+ malignancies take autologous CAR T cells ‘off the shelf’?	20
Immunotherapy approaches for malignant pleural mesothelioma	20
Advances in the management of peritoneal malignancies	20
Advancing oncolytic virus therapy by understanding the biology	19
The ten genes for breast (and ovarian) cancer susceptibility	19
Functional precision oncology using patient-derived assays: bridging genotype and phenotype	18
Validation of plasma-derived small extracellular vesicles as cancer biomarkers	18
Simultaneous development of zanubrutinib in the USA and China	18
Optimizing the safety of antibody–drug conjugates for patients with solid tumours	18
Tumour antigen-induced T cell exhaustion — the archenemy of immune-hot malignancies	17
Understanding the activity of antibody–drug conjugates in primary and secondary brain tumours	17
PARP inhibitors coming of age	17
Rare molecular subtypes of lung cancer	16

Targeting cancer with mRNA–lipid nanoparticles: key considerations and future prospects	16
Antigen presentation in cancer — mechanisms and clinical implications for immunotherapy	16
Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy	15
Barriers in access to oncology drugs — a global crisis	15
The value of anticancer drugs — a regulatory view	14
An appraisal of FDA approvals for adult solid tumours in 2017–2021: has the eagle landed?	14
Immunotherapy biomarkers: the long and winding road	14
The role of neoadjuvant therapy for resectable pancreatic cancer remains uncertain	14
Benefit from pemigatinib in cholangiocarcinoma	13
Intraoperative radiotherapy for early breast cancer — insufficient evidence to change practice	12
Improving outcomes in patients with oesophageal cancer	12
Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges	12
Optimal systemic therapy for high-risk resectable melanoma	12
Towards multi-cancer screening using liquid biopsies	11
Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship	11
Neuroendocrine neoplasms of the lung and gastrointestinal system: convergent biology and a path to better therapies	11
Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy	11
Intraoperative radiotherapy for breast cancer: powerful evidence to change practice	11
First clinical proof-of-concept that FMT can overcome resistance to ICIs	11
Tebentafusp for uveal melanoma	11
Prospective clinical deployment of machine learning in radiation oncology	11
Applications of liquid biopsy in the Pharmacological Audit Trail for anticancer drug development	10
Combination set to transform HCC therapy	10
Translating noninvasive molecular responses into clinical reality for cancer immunotherapy	9
Low-grade glioma subtypes revealed	9
Oncology approvals in 2020: a year of firsts in the midst of a pandemic	9
CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn	9
Avoiding collateral mortality in a pandemic — time to change our mindset in surgical oncology	9
Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors	9
Aumolertinib is effective in NSCLC	9
GPRC5D as a novel immunotherapeutic target in multiple myeloma	9
Risk-based oral cancer screening — lessons to be learnt	8
Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma	8
B cells and complement at the forefront of chemotherapy	8
Author Correction: EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood	8
New first-line therapy for dMMR/MSI-H CRC	8
Publisher Correction: Personalized early detection and prevention of breast cancer: ENVISION consensus statement	8
Anti-CD7 CAR T cells for T-ALL: impressive early-stage efficacy	8
Dissecting the immunogenomic biology of cancer for biomarker development	7
Early stage gastric adenocarcinoma: clinical and molecular landscapes	7
Pragmatic trials with prespecified subgroups: what oncologists can learn from COVID-19	7
Selumetinib benefits children with inoperable plexiform neurofibromas	7
Reply to ‘Intraoperative radiotherapy for breast cancer: powerful evidence to change practice’	7
Pembrolizumab for HER2+ gastric cancer	7
Molecular tumour boards — current and future considerations for precision oncology	7
Leveraging extrachromosomal DNA to fine-tune trials of targeted therapy for glioblastoma: opportunities and challenges	7
Improving quality and quantity of life for childhood cancer survivors globally in the twenty-first century	7
Belzutifan has potential in RCC	7
Value-based pricing of drugs with multiple indications or in combinations — lessons from Europe	7
Personalized treatment of immune-related adverse events — balance is required	6
Olaparib for DNA repair-deficient prostate cancer — one for all, or all for one?	6
Uncovering adagrasib resistance	6
Publisher Correction: The adenosine pathway in immuno-oncology	6
TMB — a histology-agnostic predictor of the efficacy of ICIs?	6
Exploring a new pathway for biomarker-based approval of immunotherapies	6
Drug-tolerant persister cells in cancer: the cutting edges and future directions	6
Approvals in 2021: dangling Accelerated Approvals, drug dosing, new approvals and beyond	6
Newly approved cancer drugs in China — innovation and clinical benefit	5
Author Correction: Clinical relevance of tumour-associated macrophages	5
Palliative care services at cancer centres — room for improvement	5
Publisher Correction: Lineage plasticity in cancer: a shared pathway of therapeutic resistance	5
Risk-adjusting away volume as a quality metric for surgical oncology: a perspective worth re-visiting	5
Author Correction: COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials	5
FOLFOX–HAIC active in large HCC	5
Microbial DNA signature in plasma enables cancer diagnosis	5
Cemiplimab is a new option in BCC	5
Viral gene therapy active in ovarian cancer	5
PSMA PET–CT improves staging	5
Biomarkers for immunotherapy of hepatocellular carcinoma	5
Sorafenib prevents AML relapse after allo-HSCT	5
Daratumumab in newly diagnosed MM — incorporating lessons learnt from CASSIOPEIA, MAIA and beyond	4
TNT and local recurrence in the RAPIDO trial — untangling the puzzle	4
When are results of single-arm studies dramatic?	4
Gut microbes as biomarkers of ICI response — sharpening the focus	4
Cancer vaccine induces potent T cell responses — but is it enough?	4
FDA approval standards for anticancer agents — lessons from two recent approvals in breast cancer	4
Early MRD predicts disease recurrence and benefit from adjuvant chemotherapy in CRC	4
Lorlatinib CROWNed	4
Should the control arms of randomized trials have an expiry date?	4
Sotorasib effective in KRAS-mutant NSCLC	4
Amivantamab is effective in NSCLC harbouring EGFR exon 20 insertions	4
Belzutifan is active in VHL-related cancers	4
Adjuvant olaparib — should all patients with breast cancer have genetic testing?	4
Copanlisib safe and active in combination	4
Overall survival as a primary end point in multiple myeloma trials	4
Is representation enough or should we be targeting equitable inclusion?	4
Engaging results with glofitamab	3
LAG3 inhibition improves outcomes	3
Quantitative PET-based biomarkers in lymphoma: getting ready for primetime	3
KTE-X19 efficacious in adults with B-ALL	3
Medulloblastoma: prognostic subtypes revealed	3
REACH2: ruxolitinib for refractory aGvHD	3
T-DXd active in HER2-low disease	3
Chemoradiotherapy improves NPC outcomes	3
Combination immunomodulation for immune-checkpoint-inhibitor-associated myocarditis	3